A Network Meta‐Analysis of Short and Long‐Term Efficacy of Targeted Therapy With Single or Double‐Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials

For the treatment of stage III/IV malignant melanoma (MM), a network meta-analysis (NMA) was conducted to compare the short and long-term efficacy of targeted therapy with single or double-drug regimens. All conducted randomized controlled trials (RCTs) searched from PubMed and Cochrane Library were included in the study for direct and indirect comparison for MM. The odds ratio (OR) and surface under the cumulative ranking curves (SUCRA) value of the targeted therapy with single or double-drug regimens for treatment of stage III/IV MM were also analyzed. To group the treatments according to their similarity with regards to both outcomes, cluster analyses were performed. Ultimately, 16 RCTs were incorporated for this NMA. The NMA revealed that the overall response rate (ORR) values of single-drug regimens (Vemurafenib (Vem), Dabrafenib (Dab) and Nivolumab (Niv)) were higher than those of Dacarbazine (Dac). Also the ORR values of double-drug regimens (Dab + Trametinib (Dab + Tra), Niv + Ipilimumab (Niv + Ipi) and Vem + Cobimetinib (Vem + Cob)) were moderately higher than those of Dac. The results of the SUCRA showed that short-term efficacy of single-drug regimens (Vem and Dab) were better, while the short-term efficacy of double-drug regimens (Dab + Tra and Vem + Cob) were relatively better. It was determined that Vem, Dab and Niv might be the best choice in evaluating the treatment of stage III/IV MM among different single-drug targeted therapy regimens, while Dab + Tra, Niv + Ipi and Vem + Cob might have better short-term efficacy among different double-drug targeted therapy regimens. This article is protected by copyright. All rights reserved